Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Lfb Usa IncfiledCriticalGenzyme Corp
Priority claimed from NZ568433Aexternal-prioritypatent/NZ568433A/en
Publication of NZ595351ApublicationCriticalpatent/NZ595351A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
A composition comprising antibodies, wherein the antibodies have enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, wherein the antibodies are from non-human mammalian mammary epithelial cells engineered to express the antibody, wherein the ADCC activity of the antibodies is enhanced at least two-fold compared to cell-culture derived antibodies, wherein the carbohydrates of the antibodies exhibit a high mannose glycosylation pattern, wherein at least 30% of the antibodies contain at least one oligomannose, and wherein the antibodies are of the isotype IgG1 or IgG2.
NZ595351A2005-10-212006-10-23Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
NZ595351A
(en)